Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 07-H-0030 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine metabolic and biological factors in people with Li-Fraumeni syndrome, a rare hereditary disorder that greatly increases a person's susceptibility to cancer. Patients have a mutation in the p53 tumor suppressor gene, which normally helps control cell growth. This gene may control metabolism as well as cancer susceptibility, and the study findings may help improve our understanding of not only cancer but also other conditions, such as cardiovascular function.
Healthy normal volunteers and patients with the Li-Fraumeni syndrome and their family members may be eligible for this study. Candidates must be at least 18 years of age, in overall good health and cancer-free within 1 year of entering the study. Participants undergo the following procedures:
We have previously reported that TP53 (encoding p53 protein), one of the most frequently mutated genes in human cancers, dose dependently modulates the balance between the utilization of oxidative and glycolytic pathways for energy generation in human colon cancer cells and mouse liver mitochondria. Though morphologically similar to their wild-type littermates, mice deficient in p53 display a gene dose-dependent decrease in aerobic exercise capacity, implying that p53 has functions beyond its well characterized cell cycle activities. These current findings have broad implications in fields ranging from cancer and aging research to cardiovascular physiology.
In the Li-Fraumeni familial cancer syndrome (LFS), affected individuals harbor a germline mutation in TP53, hence they are heterozygous with reduced wild-type p53 activity. We hypothesize that the heterozygous individuals will display alterations in aerobic capacity and metabolism that previously has been unappreciated. This IRB proposal translates our experimental observation to human subjects in collaboration with extramural groups studying this rare familial syndrome. The results may not only help clarify why mutations of p53 gene are so common in cancers by potentially conferring metabolic advantages in tumorigenesis, but they may also give us an opportunity to understand a fundamental regulatory mechanism in cellular energy generation relevant to other processes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| carrier LFS family members | 96 carrier LFS family members | ||
| non-carrier LFS family members or normal | 60 non-carrier LFS family members or normal | ||
| non-carrier mitochondrial disorder family members or normal controls | 20 non-carrier mitochondrial disorder family members or normal controls | ||
| normal controls for MR spectroscopy study | 30 normal controls for MR spectroscopy study | ||
| subjects with mitochondrial disorders | 20 subjects with mitochondrial disorders |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Non-invasively measure aerobic exercise capacity and metabolism | Because an interim analysis has confirmed our hypothesis, the aim of the primary endpoint has been achieved. | ongoing |
| Measure | Description | Time Frame |
|---|---|---|
| Non-invasively measure markers of mitochondrial function by magneticresonance spectroscopy (MRS) in response to transient ischemic stress | This will serve to facilitate bench-to-bedside studies to investigate metabolic and other associated changes in LFS with the goal of deriving mechanistic insights that may lead to new strategies forcancer prevention. | ongoing |
Not provided
INCLUSION CRITERIA:
Able to undserstand and sign consent
Have been diagnosed with the Li-Fraumeni Syndrome or have a family member with the Li-Fraumeni Syndrome or have been diagnosed with mitochondrial disorder or be a healthy volunteer
EXCLUSION CRITERIA:
Cancer patients undergoing or requiring systemic treatment
Not provided
Not provided
96 carrier LFS family members 60 non-carrier LFS family members or normal 30 normal controls for MR spectroscopy study 20 subjects with mitochondrial disorders 20 non-carrier mitochondrial disorder family members or normal controls
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul M Hwang, M.D. | National Heart, Lung, and Blood Institute (NHLBI) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16236959 | Background | Arena R, Myers J, Abella J, Peberdy MA. Influence of heart failure etiology on the prognostic value of peak oxygen consumption and minute ventilation/carbon dioxide production slope. Chest. 2005 Oct;128(4):2812-7. doi: 10.1378/chest.128.4.2812. | |
| 16284780 | Background | Brown BW, Costello TJ, Hwang SJ, Strong LC. Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome. Hum Genet. 2005 Dec;118(3-4):489-98. doi: 10.1007/s00439-005-0016-x. Epub 2005 Nov 12. |
| Label | URL |
|---|---|
| NIH Clinical Center Detailed Web Page | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D028361 | Mitochondrial Diseases |
| D016864 | Li-Fraumeni Syndrome |
| ID | Term |
|---|---|
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D009386 | Neoplastic Syndromes, Hereditary |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure oxygen consumption, protein and RNA levels of p53-regulated mitochondrial genes using blood cells and other tissue samples if available. | This will serve to facilitate bench-to-bedside studies to investigate metabolic and other associated changes in LFS with the goal of deriving mechanistic insights that may lead to new strategies forcancer prevention. | ongoing |
| 7033284 | Background | Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981 Dec;68(6):1456-67. doi: 10.1172/jci110398. |
| 27869650 | Derived | Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest. 2017 Jan 3;127(1):132-136. doi: 10.1172/JCI88668. Epub 2016 Nov 21. |
| 23484829 | Derived | Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU, Strong LC, Talagala SL, Balaban RS, Kang JG, Hwang PM. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med. 2013 Mar 14;368(11):1027-32. doi: 10.1056/NEJMoa1214091. |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D049914 | DNA Repair-Deficiency Disorders |